Page 91 - AWSAR 2.0

importance, which have been transferred to the industry and have progressed into the pipeline of pre-clinical toxicity and efficacy studies. For this work, our team has been awarded the prestigious Biotech Product & Process Commercialization Award-2019 from the Department of Biotechnology, Ministry of Science and Technology, Government of India.
More recently, we have been successful in isolating antibodies against an important toxic component of Naja Naja (Indian cobra) venom. This work carries immense potential and gives a hope for the development of a highly efficacious recombinant and fully
Dr Vaishali Verma || 67
human anti-venom to treat snakebites, which are currently treated using anti-venom derived from hyperimmunized horses. Such efforts will eliminate the need for immunization of horses forever.
In essence, the human antibody library developed at CIIDRET-UDSC is a unique library possessing superior characteristics than the existing libraries and matches the fervour of the ‘Make in India’ initiative in true sense. It is indeed a progressive step towards making India self-reliant for the development of new recombinant therapeutic antibody leads against clinically important targets.